The Center for Rheumatology has performed nearly 100 trials of clinical interventions for Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis since our founding in October of 2000. These trials have enabled our patients to participate in cutting-edge clinical research. Medications studied at TCFR, prior to their approval, include several of the agents now helping patients with RA throughout the world including Enbrel, Orencia, Actemra, and Xeljanz for RA and Cosentyx for Psoriatic Arthritis. Several other soon to be approved drugs have also been offered to our patients.

We are presently conducting several trials on drugs for the following conditions: RA, Spondyloarthritis and Psoriatic Arthritis.  

 If you are interested in participation in a research trial please contact The Center for Rheumatology and we can provide details.